Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial.

Journal of clinical and translational science2023PMID: 36845310

View on PubMed DOI: 10.1017/cts.2022.515

Plain Language Summary

Post hoc analysis of phase III tesamorelin trial data stratifying 26-week outcomes by presence or absence of dorsocervical fat (buffalo hump) among tesamorelin responders, finding that tesamorelin equally reduced visceral fat and waist circumference regardless of dorsocervical fat presence. Clarifies tesamorelin's utility across different HIV lipodystrophy phenotypes. Establishes that tesamorelin's visceral fat-reducing efficacy is not conditional on the co-presence of dorsocervical fat accumulation—supporting tesamorelin use in HIV patients with isolated visceral adiposity without visible dorsal fat, expanding the eligible treatment population.

Abstract

Tesamorelin, a synthetic growth hormone-releasing hormone, is indicated for the reduction of visceral adipose tissue (VAT) in people with HIV. Here, we performed a post hoc analysis of participants receiving tesamorelin for 26 weeks in a phase III clinical trial. Efficacy data were compared between individuals with and without dorsocervical fat, stratified by tesamorelin response. Among tesamorelin responders, VAT and waist circumference (WC) decreased in both dorsocervical fat groups and did not statistically differ (VAT= 0.657, WC= 0.093). These data demonstrate that tesamorelin is equally effective and should be considered in the treatment of excess VAT regardless of the presence of dorsocervical fat.

Authors

Rahman, Farah; McLaughlin, Taryn; Mesquita, Pedro; Morin, Josee; Potvin, Diane; De Chantal, Marilyn; Aberg, Judith A

Keywords

HIVantiretroviralsgrowth hormone-releasing hormonelipohypertrophytesamorelin